BIRC5 and lymphoma: Furthermore, incubation of canine OSA and lymphoma cells with anti-survivin small interfering RNA or EZN-3042 significantly reduced survivin mRNA and protein expression, increased apoptosis, inhibited proliferation, and enhanced chemotherapy sensitivity in canine OSA and lymphoma cells in vitro, [49] and with survivin reduction and increased chemotherapy efficacy in a canine OSA xenograft [21].